Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

IMVTU - Immunovant Inc Units Cons of 1 Sh + 1 Wt 18.12.24

Previous close
32.66
0   0%

Share volume: 0
Last Updated: Fri 12 Jun 2020 06:00:00 AM CEST
Financial Conglomerates: 0.01%

PREVIOUS CLOSE
CHG
CHG%
$32.66
0.00
0.00%
This ticker is disabled and data are no longer maintained and up to date.
Overview Charts Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
55%
Profitability 50%
Dept financing 50%
Liquidity 75%
Performance 55%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
0   0%
Key data
Stock price
$32.66
P/E Ratio 
N/A
DAY RANGE
$32.66 - $32.66
EPS 
$0.00
52 WEEK RANGE
$0.00 - $0.00
52 WEEK CHANGE
$0.00
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
81.812 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$0
AVERAGE 30 VOLUME 
$0
Company detail
CEO: Peter Salzmann
Region: US
Website: http://www.immunovant.com
Employees: 0
IPO year: -
Issue type:
Market: NASDAQ
Industry: Financial Conglomerates
Sector: Finance

Immunovant, Inc. is a clinical-stage biopharmaceutical company. It focuses on enabling normal lives for patients with autoimmune diseases. The company was founded in 2018 and is headquartered in New York, NY.

Recent news